These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16401681)

  • 21. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
    Lerouge D; Touboul E; Lefranc JP; Uzan S; Jannet D; Moureau-Zabotto L; Genestie C; Antoine M; Jamali M
    Cancer Radiother; 2004 Jun; 8(3):168-77. PubMed ID: 15217584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
    Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
    Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.
    Long YM; Ye S; Rong J; Xie WR
    World J Gastroenterol; 2008 Aug; 14(30):4739-44. PubMed ID: 18720533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gelsolin, NF-κB, and p53 expression in clear cell renal cell carcinoma: Impact on outcome.
    Kankaya D; Kiremitci S; Tulunay O; Baltaci S
    Pathol Res Pract; 2015 Jul; 211(7):505-12. PubMed ID: 25908108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
    Liu H; Lu L; Zhu Q; Hao Y; Mo Y; Liu M; Hu Y; Cui N; Rong T
    Radiother Oncol; 2011 May; 99(2):181-6. PubMed ID: 21620504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
    Javeri H; Arora R; Correa AM; Hofstetter WL; Lee JH; Liao Z; McAleer MF; Maru D; Bhutani MS; Swisher SG; Izzo JG; Ajani JA
    Cancer; 2008 Sep; 113(6):1302-8. PubMed ID: 18623381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and prognostic influence of NF-κB and EGFR in esophageal cancer.
    Zhang YQ; Zhang JJ; Song HJ; Li DW
    Genet Mol Res; 2015 Dec; 14(4):16819-26. PubMed ID: 26681028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
    Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.
    Sasaki N; Morisaki T; Hashizume K; Yao T; Tsuneyoshi M; Noshiro H; Nakamura K; Yamanaka T; Uchiyama A; Tanaka M; Katano M
    Clin Cancer Res; 2001 Dec; 7(12):4136-42. PubMed ID: 11751513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh GL; Vaporciyan AA; Rice DC; Bresalier RS; Roth JA; Ajani JA
    Cancer; 2006 Feb; 106(3):552-8. PubMed ID: 16353210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.
    Luthra R; Wu TT; Luthra MG; Izzo J; Lopez-Alvarez E; Zhang L; Bailey J; Lee JH; Bresalier R; Rashid A; Swisher SG; Ajani JA
    J Clin Oncol; 2006 Jan; 24(2):259-67. PubMed ID: 16344314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
    Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
    Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers of response to preoperative chemoradiation in esophageal cancers.
    Luthra R; Luthra MG; Izzo J; Wu TT; Lopez-Alvarez E; Malhotra U; Choi IS; Zhang L; Ajani JA
    Semin Oncol; 2006 Dec; 33(6 Suppl 11):S2-5. PubMed ID: 17178277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.